Association of Histopathological Markers with Clinico-Pathological Factors in Mexican Women with Breast Cancer |
Bandala, Cindy
(Division of Neuroscience, National Institute of Rehabilitation, SSA)
De la Garza-Montano, Paloma (Division of Neuroscience, National Institute of Rehabilitation, SSA) Cortes-Algara, Alfredo (Laboratory of Molecular Oncology and Oxidative Stress, Superior Medicine School of National Polytechnic Institute) Cruz-Lopez, Jaime (Military School of Graduate of Health, SEDENA) Dominguez-Rubio, Rene (Laboratory of Molecular Oncology and Oxidative Stress, Superior Medicine School of National Polytechnic Institute) Gonzalez-Lopez, Nelly Judith (Gynecology Hospital No. 3, Medical Center "La Raza", IMSS) Cardenas-Rodriguez, Noemi (Laboratory of Neurosciences (Neurochemistry), National Institute of Pediatrics, SSA) Alfaro-Rodriguez, A (Division of Neuroscience, National Institute of Rehabilitation, SSA) Salcedo, M (Unidad de Investigacion Medica en Enfermedades Oncologicas, National Center Medical "Siglo XXI", IMSS) Floriano-Sanchez, E (Military School of Graduate of Health, SEDENA) Lara-Padilla, Eleazar (Laboratory of Molecular Oncology and Oxidative Stress, Superior Medicine School of National Polytechnic Institute) |
1 | Amadou A, Torres-Mejia G, Hainaut P, Romieu I (2014). Breast cancer in Latin America: global burden, patterns, and risk factors. Salud Publica Mex, 56, 547-54 DOI |
2 | Abovaker S Kamil M (2014). Incidence of breast cancer in a primary hospital in relation to ABO blood groups system. J Med and Bioeng, 3, 74-7. |
3 | Anaya-Ruiz M, Vallejo-Ruiz V, Flores-Mendoza L, Perez-Santos M (2014). Female breast cancer incidence and mortality in Mexico, 2000-2010. Asian Pac J Cancer Prev, 15, 1477-9. DOI |
4 | Bandala C, Floriano-Sanchez E, Cardenas-Rodriguez N, et al (2012). RNA expression of cytochrome P450 in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 2647-53. DOI |
5 | Bates T, Evans T, Lagord C, Monypenny I, et al (2014). A population based study of variations in operation rates for breast cancer, of comorbidity and prognosis at diagnosis: failure to operate for early breast cancer in older women. Eur J Surg Oncol, 40, 1230-6. DOI |
6 | Cardenas-Rodriguez N, Lara-Padilla E, Bandala C, et al (2012). CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 837-46 DOI |
7 | Chavarri-Guerra Y, Villarreal-Garza C, Liedke P, et al (2012). Breast cancer in Mexico: a growing challenge to health and the health system, Lancet Oncol, 13, 335-46. DOI |
8 | Cheang MC, Chia SK, Voduc D, Gao D, et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst, 101,736-50. DOI |
9 | Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-8. DOI |
10 | De Azambuja E, Cardoso F, de Castro G Jr, et al (2007). Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96,1504-13. DOI |
11 | Dent R, Trudeau M, Pritchard KI, et al (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34 DOI |
12 |
Direccion General de Informacion en Salud (DGIS). Base de datos de defunciones 1979-2009. Sistema Nacional de Informacion en Salud (SINAIS). Available at: |
13 | Doval DC1, Sharma A, Sinha R, et al (2015). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev, 16, 4959-64. DOI |
14 | Elledge RM, Fuqua SA, Clark GM, et al (1993). Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat, 26, 225-35. DOI |
15 | Fitzmaurice C, Dicker D, Pain A, et al (2015). The global burden of cancer 2013. JAMA Oncol, 1, 505-27. DOI |
16 | Floriano-Sanchez E, Rodriguez NC, Bandala C, et al (2014). CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pac J Cancer Prev, 15, 3805-9. DOI |
17 | Frebourg T, Friend SH (1993). The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence? J Natl Cancer Inst, 85, 1554-57. DOI |
18 | Gates MA, Xu M, Chen WY, Kraft P, Hankinson SE (2012). Wolpin BM. ABO blood group and breast cancer incidence and survival. Int J Cancer, 130, 2129-37. DOI |
19 | Ji Y, Sheng L, Du X, Qiu G, Chen B, Wang X (2014). Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer. J Thorac Dis, 6, 896-904. |
20 | Hsiao YH, Siddiqui S, Man YG (2010). Dual use of a single Wilms' tumor 1 immunohistochemistry in evaluation of ovarian tumors: a preliminary study of 20 cases. J Cancer, 13, 93-7. |
21 | Justo N, Wilking N, Jonsson B, et al (2013). A review of breast cancer care and outcomes in Latin America. Oncologist, 18, 248-56. DOI |
22 | Keyhani E, Muhammadnejad A, Behjati F, Sirati F (2013). Pazhoomand. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents. Asian Pac J Cancer Prev, 14, 7651-6. DOI |
23 | Kurshumliu F, Gashi-Luci L, Kadare S, Alimehmeti M and Gozalan U (2014). Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant differences in immunohistochemical marker expression. World J Surg Oncol, 12, 1-5. DOI |
24 | Lane DP (1992). Cancer. p53, guardian of the genome. Nature, 358, 15-6. DOI |
25 | Leon-Hernandez SR, Padilla EL, Algara AC, et al (2014). Relation of alcohol/tobacco use with metastasis, hormonal (estrogen and progesterone) receptor status and c-erbB2 protein in mammary ductal carcinoma. Asian Pac J Cancer Prev, 15, 5709-14. DOI |
26 |
Maschio LB, Madallozo BB, Capellasso BA, et al (2014). Immunohistochemical investigation of the angiogenic proteins VEGF, HIF-1 |
27 | Nigro JM, Baker SJ, Preisinger AC, et al (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature, 342, 705-8. DOI |
28 | Perez-Santos JL, Anaya-Ruiz M (2013). Mexican breast cancer research output, 2003-2012. Asian Pac J Cancer Prev, 14, 5921-3. DOI |
29 | Niikura N, Iwamoto T, Masuda S, et al (2012). Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci, 103, 1508-12. DOI |
30 | Ohno S, Chow LW, Sato N, et al (2013). Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat, 142, 69-80. DOI |
31 | Petric M, Martinez S, Acevedo F, et al (2014). Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy. Asian Pac J Cancer Prev, 15, 10277-80 |
32 | Pervaiz F, Rehmani S, Majid S, Anwar H (2015). Evaluation of Hormone Receptor Status (ER/PR/HER2-neu) in Breast Cancer in Pakistan. J Pak Med Assoc, 65, 747-52. |
33 | Rummel S, Shriver CD, Ellsworth RE (2012). Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. BMC Med Genet, 13, 41. |
34 | Seshie B, Adu-Aryee NA, Dedey F, Calys-Tagoe B, Clegg-Lamptey JN (2015). A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol, 15, 14. DOI |
35 | Shui R, Yu B, Bi R, Yang F, Yang W (2015). An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer. PLoS One, 10, 125131. |
36 | Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al (2013). Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist, 18, 1298-306. DOI |
37 | Tirona MT, Sehgal R, Ballester O (2010). Prevention of breast cancer (part I): Epidemiology, risk factors, and risk assessment tools. Cancer Invest, 28, 743-50. DOI |
38 | Thor AD, Moore DH II, Edgerton SM, et al (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst, 84, 845-55. DOI |
39 | Thorlacius S, Borresen AL, Eyfjord JE (1993). Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res, 53, 1637-41. |
40 | von Minckwitz G, Schmitt WD, Loibl S, Muller BM, Blohmer JU, Sinn BV, et al (2013). Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res, 19, 4521-31. DOI |
41 | Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83. DOI |
42 | Zhang BL, He N, Huang YB, Song FJ, Chen KX (2014). ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 4643-50. DOI |
43 | Zheng,YZ, Wang L, Hu X, Shao ZM (2015). Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. Oncotarget, 2015. www.impactjournals.com/oncotarget. |
![]() |